Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07511816 | A Study of LY4515100 in Participants With Pain Following Third Molar Removal | PHASE2 | RECRUITING | 212 | — | — | Apr 1, 2026 | Dec 1, 2026 | May 1, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| LY4515100 | EXPERIMENTAL | Administered Orally |
| Placebo | PLACEBO_COMPARATOR | Administered Orally |
| Name | Type | Description |
|---|---|---|
| LY4515100 | DRUG | Administered Orally |
| Placebo | DRUG | Administered Orally |
Inclusion Criteria: * Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg/m²) inclusive. * Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray. Exclusion...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | NA | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | — | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | — | Flozin |